Tianjin Pharmaceutical Da Ren Tang's (SGX:T14) attributable profit to owners during the third quarter of the year jumped 54% to 224.6 million yuan from 146.1 million a year earlier, according to a Thursday filing with the Singapore Exchange.

Earnings per share rose to 0.30 yuan per share compared with 0.19 yuan in the comparable period.

Revenue fell 38% year over year to 1.02 billion yuan from 1.65 billion yuan, mainly due to a change in the company's consolidation scope which excluded data of Tianjin Zhongxin Medicine.

The directors proposed to seek approval form shareholders for an interim dividend of 24.5 yuan per share for every ten shares in the company's capital.

Shares of the company were up nearly 3% at the close of trading on Thursday.